UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 463

Sortiert nach

PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression

Clinical cancer research, 2017-07, Vol.23 (14), p.3711-3720

2017

Volltextzugriff (PDF)

Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian

Cancer, 2015-01, Vol.121 (2), p.269-275

2015

Volltextzugriff (PDF)

Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial

The lancet oncology, 2020-10, Vol.21 (10), p.1269-1282

2020

Volltextzugriff (PDF)

BRCA mutation genetic testing implications in the United States

Breast (Edinburgh), 2017-02, Vol.31, p.224-232

2017

Volltextzugriff (PDF)

American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility

Journal of clinical oncology, 2015-11, Vol.33 (31), p.3660-3667

2015

Volltextzugriff (PDF)

Helping Patients Understand and Cope with BRCA Mutations

Current oncology reports, 2022-06, Vol.24 (6), p.733-740

2022

Volltextzugriff (PDF)

Hematologic malignancies in Li–Fraumeni syndrome: A case report

American journal of medical genetics. Part A, 2024-07, Vol.194 (7), p.e63573-n/a

2024

Volltextzugriff (PDF)

Clinical and Pathologic Characteristics of Patients With BRCA-Positive and BRCA-Negative Breast Cancer

Journal of clinical oncology, 2008-09, Vol.26 (26), p.4282-4288

2008

Volltextzugriff (PDF)

Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant

Journal of clinical oncology, 2020-02, Vol.38 (5), p.388-394

2020

Volltextzugriff (PDF)

Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer

Cancer research (Chicago, Ill.), 2015-11, Vol.75 (22), p.4863-4875

2015

Volltextzugriff (PDF)

Inflammatory breast cancer: a proposed conceptual shift in the UICC–AJCC TNM staging system

The lancet oncology, 2017-04, Vol.18 (4), p.e228-e232

2017

Volltextzugriff (PDF)

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

The Lancet (British edition), 2010-07, Vol.376 (9737), p.235-244

2010

Volltextzugriff (PDF)

Clinical practice guidelines for BRCA1 and BRCA2 genetic testing

European journal of cancer (1990), 2021-03, Vol.146, p.30-47

2021

Volltextzugriff (PDF)

Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer

Clinical cancer research, 2011-03, Vol.17 (5), p.1082-1089

2011

Volltextzugriff (PDF)

Validation of a personalized risk prediction model for contralateral breast cancer

Breast cancer research and treatment, 2018-07, Vol.170 (2), p.415-423

2018

Volltextzugriff (PDF)

Contralateral Risk-Reducing Mastectomy in Breast Cancer Patients Who Undergo Multigene Panel Testing

Annals of surgical oncology, 2020-11, Vol.27 (12), p.4613-4621

2020

Volltextzugriff (PDF)

ASO Visual Abstract: Other Primary Malignancies in Patients with Breast Cancer Who Undergo Germline Panel Testing

Annals of surgical oncology, 2023-03, Vol.30 (3), p.1669-1670

2023

Volltextzugriff (PDF)

Germline BRCA1/BRCA2 mutations among high risk breast cancer patients in Jordan

BMC cancer, 2018-02, Vol.18 (1), p.152-152, Article 152

2018

Volltextzugriff (PDF)

Increasing referral of at‐risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center

Cancer, 2022-01, Vol.128 (1), p.94-102

2022

Volltextzugriff (PDF)

Protein-folding chaperones predict structure-function relationships and cancer risk in BRCA1 mutation carriers

Cell reports (Cambridge), 2024-02, Vol.43 (2), p.113803-113803, Article 113803

2024

Volltextzugriff (PDF)

Association Between Plasma Diacetylspermine and Tumor Spermine Synthase With Outcome in Triple-Negative Breast Cancer

JNCI : Journal of the National Cancer Institute, 2020-06, Vol.112 (6), p.607-616

2020

Volltextzugriff (PDF)

miRacle of microRNA-Driven Cancer Nanotherapeutics

Cancers, 2022-08, Vol.14 (15), p.3818

2022

Volltextzugriff (PDF)

Use of breast surveillance between women with pathogenic variants and variants of uncertain significance in breast cancer susceptibility genes

Cancer, 2022-10, Vol.128 (20), p.3709-3717

2022

Volltextzugriff (PDF)

Contralateral Prophylactic Mastectomy among Women with Pathogenic Variants in BRCA1/2: Overall Survival, Racial, and Ethnic Differences

The breast journal, 2022, Vol.2022, p.1447545-9

2022

Volltextzugriff (PDF)

Cancer Incidence in First‐ and Second‐Degree Relatives of BRCA1 and BRCA2 Mutation Carriers

The oncologist (Dayton, Ohio), 2016-07, Vol.21 (7), p.869-874

2016

Volltextzugriff (PDF)

1 – 25 von 463

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(436)
Mit Volltextzugriff
(435)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(89)
Cancer
(42)
Cancer Research
(35)
Breast Cancer Research And Treatment
(29)
Clinical Cancer Research
(18)
Cancer Prevention Research
(17)
The Breast Journal
(14)
The breast Journal
(11)
Annals Of Surgical Oncology
(8)
The Oncologist
(8)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression

Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian

Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial

BRCA mutation genetic testing implications in the United States

American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility

Helping Patients Understand and Cope with BRCA Mutations

Hematologic malignancies in Li–Fraumeni syndrome: A case report

Clinical and Pathologic Characteristics of Patients With BRCA-Positive and BRCA-Negative Breast Cancer

Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant

Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer

Inflammatory breast cancer: a proposed conceptual shift in the UICC–AJCC TNM staging system

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

Clinical practice guidelines for BRCA1 and BRCA2 genetic testing

Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer

Validation of a personalized risk prediction model for contralateral breast cancer

Contralateral Risk-Reducing Mastectomy in Breast Cancer Patients Who Undergo Multigene Panel Testing

ASO Visual Abstract: Other Primary Malignancies in Patients with Breast Cancer Who Undergo Germline Panel Testing

Germline BRCA1/BRCA2 mutations among high risk breast cancer patients in Jordan

Increasing referral of at‐risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center

Protein-folding chaperones predict structure-function relationships and cancer risk in BRCA1 mutation carriers

Association Between Plasma Diacetylspermine and Tumor Spermine Synthase With Outcome in Triple-Negative Breast Cancer

miRacle of microRNA-Driven Cancer Nanotherapeutics

Use of breast surveillance between women with pathogenic variants and variants of uncertain significance in breast cancer susceptibility genes

Contralateral Prophylactic Mastectomy among Women with Pathogenic Variants in BRCA1/2: Overall Survival, Racial, and Ethnic Differences

Cancer Incidence in First‐ and Second‐Degree Relatives of BRCA1 and BRCA2 Mutation Carriers

Suchergebnisse filtern